Navigation Links
Got calcium? UWM researcher finds that food labels confuse consumers
Date:10/5/2007

Current food labeling leads to under-consumption of calcium, according to this study. Those who were taught how to translate the information consumed more. Researchers believe the same is true for other beneficial nutrients.

A woman at risk for osteoporosis is told by her doctor to get 1,200-1,500 milligrams of calcium every day. But when she looks at the Nutrition Facts panel on a carton of yogurt or a jug of milk, she finds that calcium is only listed by Percent Daily Value (%DV).

How does she convert that to milligrams?

If shes like most of usshe cant. And neither can her doctor.

Those were among the findings of research conducted by Laura A. Peracchio, professor of marketing at the University of Wisconsin-Milwaukee (UWM), and Lauren Block, professor of marketing at Baruch College (CUNY). The results were so compelling that the U.S. Food and Drug Administration added information to its Web site on how to translate %DV to milligrams.

The problem

The research, which involved three separate studies and a follow-up, is discussed in The Calcium Quandary: How Consumers Use Nutrition Labels for Daily Diet, published in the Journal of Public Policy and Marketing. Peracchio and Block found that:

  • In Study 1, only two of 37 respondents correctly translated the calcium information on a carton of yogurt from %DV to milligrams.

  • In Study 2, when 20 physicians were shown the same label, only six gave the right answer in milligrams. (Asked how the calculation was done, one physician who gave an incorrect answer replied: I have no idea. I made it up.) Yet most doctors dispense calcium recommendations to their patients in milligrams.

The central question of the research, Peracchio and Block write, is: How do consumers make food consumption decisions when product information falls short of providing the nutritional knowledge needed for personal health consumption g
'/>"/>

Contact: Laura Peracchio
lperacch@uwm.edu
414-229-3830
University of Wisconsin - Milwaukee
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Researchers discover way to make cells in the eye sensitive to light
2. Researchers find how protein allows insects to detect and respond to pheromones
3. Researchers Uncover Key Step In Manufacture of Memory Protein
4. U of M researcher examines newly emerging deadly disease
5. NYU researchers simulate molecular biological clock
6. Researchers reveal the infectious impact of salmon farms on wild salmon
7. Researchers identify target for cancer drugs
8. Vital step in cellular migration described by UCSD medical researchers
9. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
10. UCSD researchers maintain stem cells without contaminated animal feeder layers
11. Researchers discover molecule that causes secondary stroke

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)... , Sewer overflows are a nasty business, posing d...Carolina State University is launching a new proje...tion Agency (EPA) that targets the fat and grease ...r, and will give urban planners new tools to furth...are overflows from "sanitary" sewer systems, as op...
(Date:11/22/2009)... , CINCINNATI -- Children exposed prenatally to t...articularly high risk for ADHD, according to resea... Center. , The study estimates that up to 35 per... 8 and 15 could be reduced by eliminating both of ...e into up to 800,000 children , "Tobacco and le...
(Date:11/22/2009)... , A commonly inherited gene deletion can increas... bone marrow transplantation, an international tea...e online issue of Nature Genetics . When the gene...me but present in the recipient,s, transplants hav...ffect known as graft-versus-host disease, in which...
Breaking Biology News(10 mins):Lose the fat: Targeting grease to curtail sewer overflows 2Exposure to lead, tobacco smoke raises risk of ADHD 2Gene mismatch influences success of bone marrow transplants 2Gene mismatch influences success of bone marrow transplants 3Gene mismatch influences success of bone marrow transplants 4BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis 4678 1BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis 4678 2Reverse Ages Staying Young Naturally 50696 1ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB 402 4677 1ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB 402 4677 2ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB 402 4677 3ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB 402 4677 4ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB 402 4677 5
...ctors from different hospitals can collaborate on ...rating room. What if doctors in remote locations c...cialists in hospitals around the world? , This en...search by a multi-university partnership that is t...dvanced networking consortium Internet2. , Roche...
...g is causing the worldwide declines of amphibians ...cording to biologists. The findings, which contrad...is killing the frogs and toads and aid in their co... sixth mass extinction event," said Peter Hudson, ...d co-author of the research study. "And amphibians...
...matodes are extreme parasites. These microscopic, ...ral and field crops in sub-tropical regions, resul...d gardeners. , Until recently, fumigation of the ...rimary method for controlling root-knot nematodes ... is an odorless, colorless gas that has been widel...
Other Biology News:The next step in health care: Telemedicine 2Global warming link to amphibian declines in doubt 2Global warming link to amphibian declines in doubt 3Parasite-resistant peppers green alternatives to chemical pesticides 2
(Date:11/19/2009).../ - Aegera Therapeutics Inc. announced today the d...B study of AEG35156, a targeted antisense therapeu... indications. ,, The study, entitled "An Open-L...bitor of Apoptosis (XIAP) Antisense AEG35156 Given...ubicin in AML Following Failure of a Single Standa...
(Date:11/19/2009)...ne Synthesis Companies Form International Gene Syn...ces in Risk Reduction ,Five Member Companies Rep...city , (PRWEB) November 1...synthesis companies today announced agreement that...omote biosecurity in the gene synthesis industry. ...
(Date:11/19/2009)...mber 19 AFFiRiS AG will focus its,...te at an unexpectedly early,stage of development: ...o,Phase II clinical trial early in 2010. This deci...tion of two Phase I trials with the candidates,AD0... the first interim,analysis of the secondary endpo...
(Date:11/18/2009)... Standards and Technology (NIST) has demonstrated ...ing and measuring elusive hazards such as conceale...d or pesticides distributed in soil by wind and ra...nventional techniques for detecting traces of thes...having distinct electrically positive and negative...
Breaking Biology Technology:Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3Prototype NIST method detects and measures elusive hazards 2
...ent, BASEL, Switzerland and TUCSON, Ariz., Jan. 2...d-leading healthcare,provider of pharmaceuticals a...ana") (Nasdaq: VMSI ) today announced that they h...e terms of the agreement, Roche will,increase the ...mon shares,to $89.50 per share in cash (or an aggr...
...x,Orthobiology B.V. announced today the closure of...y BioGeneration Ventures., Progentix Orthobiology...e suite of osteoinductive material products for cl...rogentix bone graft material is based on,surface s...the ability to,attract growth factors and stems ce...
...s,announced that it will continue to provide Avast...thalmologists who request it for their patients.,T..., Genentech,s, decision,( http://www.lucentis.com/...Avastin directly to compounding pharmacies as of J...tinal specialists and,ophthalmologists to treat ag...
Other Biology Technology:Roche to Acquire Ventana for $89.50 per share 2Roche to Acquire Ventana for $89.50 per share 3Roche to Acquire Ventana for $89.50 per share 4Roche to Acquire Ventana for $89.50 per share 5Roche to Acquire Ventana for $89.50 per share 6Progentix Orthobiology B.V. Closes Series A Financing Round 2Wedgewood Pharmacy Will Continue to Provide Avastin(R) to Ophthalmologists and Retinal Specialists 2Wedgewood Pharmacy Will Continue to Provide Avastin(R) to Ophthalmologists and Retinal Specialists 3
Eosinophil Chip-IHC from 3H Biomedical AB
B Cell Chip-IHC from 3H Biomedical AB
Basophil Chip-IHC from 3H Biomedical AB
UCB CD4 T Cell Chip-IHC from 3H Biomedical AB
Biology Products: